)
Visual21 Nov 2025
Data center suppliers
Gentian Diagnostics (GENT) investor relations material
Gentian Diagnostics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary23 Oct, 2025
Executive summary
Q3 2025 sales reached NOK 41.8 million, up 28% year-over-year, with strong growth in the U.S. and recovery in China; YTD sales were NOK 129.9 million, up 19%.
EBITDA for Q3 2025 was NOK 8.4 million, up from NOK 5.0 million in Q3 2024; YTD EBITDA reached NOK 24.1 million, up from NOK 16.5 million.
Cystatin C sales grew 73% in Q3 2025, with robust adoption, especially in the U.S.; fCAL turbo sales rose 11%.
NT-proBNP assay advanced to final verification, with commercial launch targeted for Q4 2026 and research-use-only version by end-2025.
Major IVD company partnership project moved from proof-of-concept to optimization; JIA COMPASS study for GCAL in juvenile idiopathic arthritis enrolled 70 patients.
Financial highlights
Q3 2025 sales: NOK 41.8 million (+28% YoY); YTD sales: NOK 129.9 million (+19% YoY).
EBITDA for Q3: NOK 8.4 million; YTD EBITDA: NOK 24.1 million (+46% YoY).
Gross margin recovered to 56% in Q3 2025, up from 52% in Q3 2024.
Net profit for Q3 2025 was NOK 4.0 million; YTD net profit was NOK 9.8 million.
Cash and cash equivalents stood at NOK 86.6 million at quarter-end; equity ratio was 86.8%.
Outlook and guidance
U.S. market expected to remain a key growth driver, with less than 10% hospital adoption of Cystatin C, indicating significant potential.
Full commercial launch of NT-proBNP assay expected in Q4 2026, with research-use-only version by end-2025.
Cautious outlook for China and Asia due to regulatory changes ("unbundling" and VBP), but no major decline expected.
Company aims to grow gross margin to 60%+ and achieve long-term EBITDA margins of 40%.
The addressable market for targeted disease groups is estimated at USD 5.9 billion, growing 5-10% annually.
NT-proBNP launch: risks to 4Q26 timeline?
China unbundling policy: long-term strategy?
Path to 60%+ gross margin?
Mitigation strategy for China's unbundling?
NT-proBNP calibrator stability resolution timeline?
U.S. Cystatin C market penetration strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Gentian Diagnostics earnings date
Q4 202511 Feb, 2026
Next Gentian Diagnostics earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Gentian Diagnostics ASA is a Norwegian company that specializes in the development and production of in-vitro diagnostic (IVD) reagents. The company’s focus is on creating biochemical reagents for use in clinical chemistry analyzers, particularly utilizing Particle-Enhanced Turbidimetric Immunoassays (PETIA). These assays enable faster, automated testing for various medical conditions, improving operational efficiency for clinical labs. Gentian’s products target key areas such as infections, inflammation, kidney disease, cardiac conditions, and veterinary medicine. Gentian Diagnostics is headquartered in Moss, Norway, and its shares are listed on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage